NCT00063843View on ClinicalTrials.gov

Anthrax-rPA: Safety, Tolerability, Immunogenicity

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

August 31, 2005

Conditions
Anthrax
Interventions
BIOLOGICAL

Recombinant Protective Antigen, Anthrax Vaccine Adsorbed

Trial Locations (1)

21201

University of Maryland School of Medicine, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00063843 - Anthrax-rPA: Safety, Tolerability, Immunogenicity | Biotech Hunter | Biotech Hunter